Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention
Open Access
- 20 January 2020
- journal article
- research article
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 7 (2) , 1709389
Abstract
Targeting metabolic reprogramming has emerged as a promising strategy for therapeutic intervention in cancer. We identify that fatty acid synthase (FASN) is essential for cancer initiation playing a critical role in acquiring three-dimensional (3D) growth properties during transformation. In vivo inhibition of FASN before oncogenic activation prevents tumor development and invasive growth suggesting that FASN could be a potential target for cancer prevention.Keywords
This publication has 10 references indexed in Scilit:
- Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cellsNature Communications, 2019
- Orlistat as a FASN inhibitor and multitargeted agent for cancer therapyExpert Opinion on Investigational Drugs, 2018
- Reductive carboxylation supports redox homeostasis during anchorage-independent growthNature, 2016
- Molecular Pathways: Fatty Acid SynthaseClinical Cancer Research, 2015
- Fatty Acid Synthase Modulates Intestinal Barrier Function through Palmitoylation of Mucin 2Cell Host & Microbe, 2012
- Exemestane for Breast-Cancer Prevention in Postmenopausal WomenNew England Journal of Medicine, 2011
- Fatty acid synthase and the lipogenic phenotype in cancer pathogenesisNature Reviews Cancer, 2007
- Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotypeHuman Pathology, 2007
- Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.2004
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998